| Primary |
| Non-small Cell Lung Cancer |
29.2% |
| Hypertension |
9.7% |
| Constipation |
8.7% |
| Pain |
8.5% |
| Nausea |
7.8% |
| Prophylaxis |
5.6% |
| Insomnia |
3.0% |
| Diarrhoea |
2.9% |
| Back Pain |
2.7% |
| Lung Neoplasm Malignant |
2.6% |
| Anxiety |
2.4% |
| Supplementation Therapy |
2.4% |
| Cough |
2.1% |
| Chronic Obstructive Pulmonary Disease |
1.9% |
| Vomiting |
1.9% |
| Diabetes Mellitus |
1.8% |
| Gastrooesophageal Reflux Disease |
1.8% |
| Pulmonary Embolism |
1.8% |
| Hyperlipidaemia |
1.7% |
| Hypothyroidism |
1.7% |
|
| Death |
22.8% |
| Interstitial Lung Disease |
11.3% |
| Non-small Cell Lung Cancer |
6.3% |
| Cytolytic Hepatitis |
6.0% |
| Pulmonary Embolism |
5.0% |
| Neoplasm Malignant |
4.6% |
| Respiratory Failure |
4.6% |
| Disease Progression |
4.0% |
| Vomiting |
4.0% |
| Dehydration |
3.3% |
| Hepatotoxicity |
3.3% |
| Deep Vein Thrombosis |
3.0% |
| Dyspnoea |
3.0% |
| Hyponatraemia |
3.0% |
| Convulsion |
2.6% |
| Diarrhoea |
2.6% |
| Haemoptysis |
2.6% |
| Nausea |
2.6% |
| Pneumonia |
2.6% |
| Renal Failure Acute |
2.6% |
|
| Secondary |
| Non-small Cell Lung Cancer |
22.3% |
| Pain |
11.7% |
| Constipation |
11.0% |
| Hypertension |
6.5% |
| Nausea |
6.3% |
| Gastrointestinal Pain |
5.9% |
| Product Used For Unknown Indication |
4.1% |
| Insomnia |
3.3% |
| Anxiety |
3.0% |
| Back Pain |
2.8% |
| Hyperlipidaemia |
2.6% |
| Prophylaxis |
2.6% |
| Supplementation Therapy |
2.6% |
| Hypothyroidism |
2.4% |
| Vomiting |
2.4% |
| Depression |
2.2% |
| Gastrooesophageal Reflux Disease |
2.2% |
| Bronchial Carcinoma |
2.0% |
| Lung Adenocarcinoma Metastatic |
2.0% |
| Diarrhoea |
1.9% |
|
| Hepatic Function Abnormal |
9.3% |
| Gastric Ulcer |
8.1% |
| Transaminases Increased |
8.1% |
| Non-small Cell Lung Cancer |
7.0% |
| Pneumonia |
7.0% |
| Urinary Tract Infection |
7.0% |
| Cytolytic Hepatitis |
5.8% |
| Lower Respiratory Tract Infection |
4.7% |
| Oedema Peripheral |
4.7% |
| Orthostatic Hypotension |
4.7% |
| Basal Cell Carcinoma |
3.5% |
| Decreased Appetite |
3.5% |
| Diarrhoea Haemorrhagic |
3.5% |
| Gastritis |
3.5% |
| Interstitial Lung Disease |
3.5% |
| Large Intestine Perforation |
3.5% |
| Pleural Effusion |
3.5% |
| Viral Infection |
3.5% |
| Visual Acuity Reduced |
3.5% |
| Autoimmune Hepatitis |
2.3% |
|
| Concomitant |
| Non-small Cell Lung Cancer |
17.5% |
| Lung Neoplasm Malignant |
15.8% |
| Drug Use For Unknown Indication |
12.3% |
| Product Used For Unknown Indication |
12.3% |
| Multiple Myeloma |
8.8% |
| Gastrointestinal Carcinoma |
7.0% |
| Deep Vein Thrombosis |
3.5% |
| Metastases To Bone |
3.5% |
| Nausea |
3.5% |
| Prophylaxis |
3.5% |
| Transient Ischaemic Attack |
3.5% |
| Constipation |
1.8% |
| Hypotension |
1.8% |
| Mineral Supplementation |
1.8% |
| Pain |
1.8% |
| Thromboembolism Prophylaxis |
1.8% |
|
| Haematoma |
20.0% |
| Vision Blurred |
20.0% |
| Hypocalcaemia |
10.0% |
| Metastasis |
10.0% |
| Off Label Use |
10.0% |
| Urinary Retention |
10.0% |
| Vomiting |
10.0% |
| White Blood Cell Count Decreased |
10.0% |
|
| Interacting |
| Angiogram |
39.3% |
| Non-small Cell Lung Cancer |
39.3% |
| Bipolar I Disorder |
7.1% |
| Depression |
7.1% |
| Neoplasm Malignant |
7.1% |
|
| Drug Interaction |
38.5% |
| Sinus Bradycardia |
38.5% |
| Multi-organ Failure |
15.4% |
| Electrocardiogram Qt Prolonged |
7.7% |
|
